Bcl-2 Expression and Chemotherapy Response in Colorectal Cancer
Author Information
Author(s): HJ Schneider, SA Sampson, D Cunningham, AR Norman, HJN Andreyev, JVT Tilsed, PA Clarke
Primary Institution: Royal Marsden Hospital and Cancer Research Campaign Centre for Cancer Therapeutics, Institute of Cancer Research
Hypothesis
Does bcl-2 expression influence response to chemotherapy in colorectal adenocarcinomas?
Conclusion
Bcl-2 expression does not significantly influence response to chemotherapy or survival in patients with colorectal adenocarcinoma.
Supporting Evidence
- 149 out of 231 tumors (64.5%) overexpressed bcl-2.
- Bcl-2 expression was associated with low plasma CEA levels (P=0.013).
- Bcl-2 expression did not influence overall survival or response to chemotherapy.
Takeaway
This study looked at whether a protein called bcl-2 affects how well chemotherapy works for colorectal cancer, and it found that it doesn't really make a difference.
Methodology
The study analyzed bcl-2 expression in 231 colorectal tumors from patients treated with surgery alone or with chemotherapy.
Limitations
The study did not find a significant association between bcl-2 expression and survival or response to chemotherapy.
Statistical Information
P-Value
P=0.013 for plasma CEA levels; P=0.049 for differentiation
Want to read the original?
Access the complete publication on the publisher's website